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Purpose: To determine the optimal surgical strategies in reoperative infrainguinal bypass, 
we reviewed our results in 300 consecutive secondary bypasses in 251 patients operated 
on between Jan. 1, 1975, and Nov. 1, 1993. 
Methods: There were 168 men (67%) and 83 women (33%), with a mean age of 64.8 years 
and a typical distribution of risk factors including smoking (76.4%), diabetes (33.7%), and 
coronary artery disease (47.1%). The indications for surgery were limb-threatening 
ischemia in 83.5% and severe claudication i  16.5% of patients. The majority of conduits 
(n = 213) were autogenous vein and were composed of a single segment of greater 
saphenous vein in 121 bypasses (57%) and various alternative veins including composite, 
arm, and lesser saphenous vein in 92 bypasses (43%). Prosthetic onduits included 69
polytetrafluoroethylene, 16 umbilical vein, and two Dacron grafts. 
Results: There was one perioperative d ath (0.3%) and a 25% total morbidity rate includ- 
ing a 1.7% myocardial infarction rate. There was a 28.6% early ( < 30 days) graft failure 
and 10.7% early amputation rate for prosthetic bypass grafts compared with 13.6% early 
graft failure and 5.6% early amputation rates for vein grafts. Autogenous vein bypasses had 
higher 5-year secondary patency rates than had prosthetic grafts (51.5% -+ 4.6% vs 
27.4% -+ 6.1%, p < 0.001 ). Results with autogenous vein bypass improved significantly 
from the 1975 to 1984 to the 1985 to 1993 interval with 5-year secondary patency rates 
increasing from 38.3% -+ 6.9% to 59.1% -+ 5.8% (do = 0.017) and 5-year limb-salvage 
rates increasing from 40.4% -+ 7.6% to 72.4% -+ 6.6% (p < 0.001). Vein grafts to the 
popliteal and tibial outflow levels had equivalent long-term results. Vein grafts completed 
for claudication demonstrated results superior to those for limb salvage, with a 5-year 
secondary patency rate of 75.8% -+ 8.1% versus 52.3% -+ 7.9% (p = 0.048). Secondary 
autogenous vein bypass grafting performed after early primary graft failure (< 3 months) 
did particularly poorly, with only a27.2% -+ 7.7% 4-year secondary patency rate. Greater 
saphenous veins tended to perform better than alternative vein bypasses, with a 5-year 
secondary patency rate of 68.5% -+ 6.0% compared with 48.3% -+ 10.5% (p = 0.09)and 
a 5-year limb-salvage rate of 77.8% -+ 7.4% versus 54.2% -+ 11.8% (p = 0.046). 
Conclusions: When patients uffer a recurrence of limb-threatening ischemia t the time of 
infrainguinal graft failure, aggressive attempts at secondary revascularization with 
autogenous vein are warranted based on the low surgical morbidity and mortality rates and 
the improved patency and limb salvage rates that are currently attainable. (J VAsc SURG 
1995;21:282-95.) 
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Despite continued advances in vascular surgical 
techniques and the resultant improvement in in- 
frainguinal bypass graft patency, thrombosis of 
femoropopliteal nd femorotibial bypass grafts re- 
mains a distressing and challenging problem for all 
vascular surgeons. Early graft failure (< 30 days 
after surgery) has been reported in 5% to 20% of 
cases, x'2 whereas intermediate o late graft failure of 
vein grafts (> 30 days after surgery) has occurred 
in 20% to 50% of cases within 5 years of surgery. 3~ 
Thrombosis of infrainguinal bypass grafts usually 
results in a recrudescence of ischemic symptoms 
ranging from claudication to limb-threatening isch- 
emia. In a previous review we noted that 10% of 
our patients underwent major amputation as the 
next intervention after failure of the infrainguinal 
reconstruction. 6 
The relatively high incidence of this complication 
and the major impact it has on our patients mandates 
an aggressive and effective management regimen. For 
those patients who have severe ischemia t the time 
of graft failure, the available therapeutic options have 
offered suboptimal results. Restoration of long-term 
patency to thrombosed vein or prosthetic infrain- 
guinal bypass grafts with either thrombectomy or
thrombolytic therapy has proved difficult. 713 Given 
our inability to restore patency effectively to failed 
infrainguinal bypass grafts after graft thrombosis, it
would appear that replacement of the failed graft with 
an entirely new bypass (i.e., a secondary bypass) is the 
best therapeutic option. Unfortunately, the results 
that have been achieved historically with secondary 
bypass have been markedly inferior to those after 
primary bypass grafting, with 5-year primary patency 
rates of 37% to 57%. 8'1417 
To determine the optimal strategies of secondary 
infrainguinal bypass, we reviewed our experience 
with 300 consecutive secondary bypass grafts after 
primary infrainguinal graft failure. Emphasis was 
placed on improvements achieved over time as 
surgical techniques have evolved. Comparisons be- 
tween results achieved with various alternative con- 
duits were also made to establish the preferred 
approach in patients who lack the ipsilateral greater 
saphenous vein (GSV). 
METHODS AND PATIENTS 
From Jan. I, 1975, to Nov. 1, 1993, a total of 300 
secondary infrainguinal bypass procedures in 251 
patients were performed to replace previously failed 
bypass grafts. The bypasses in this series included 272 
first-time reoperations, 20 second-time r operations, 
and eight third or fourth reoperations. One hundred 
ninety-one of the original bypass procedures (64%) 
were performed by us, whereas the remaining 109 
(36%) were referred after failure of grafts performed 
elsewhere. Sixty-seven percent of the patients were 
men and 33% were women, with a mean age of 64.8 
years. The patients demonstrated the typical distri- 
bution of risk factors for peripheral vascular disease 
including tobacco use (76.4%), diabetes mellims 
(33.7%), hypertension (51.8%), coronary artery 
disease (47.1%, including an 11.1% incidence of 
prior coronary artery bypass), chronic obstructive 
pulmonary disease (16.5%), and previous stroke 
(5.7%). The indications for secondary bypass in- 
cluded severe claudication in 16.5% and critical 
ischemia in 83.5% of the patients (including rest pain 
[52.9%], ischemic ulceration [19.2%], and gangrene 
[11.4%]). 
The conduits employed included autogenous vein 
in 213 bypasses (71%) (Table I) and prosthetic graft 
in 87 cases (29%) (Table II). Autogcnous conduits 
were constructed of GSV including in situ, nonre- 
versed translocated, reversed, and composite GSV in 
133 cases (62%). Forty-six grafts (21%) were con- 
structed predominantly of arm vein (basilic or 
cephalic), including single-segment arm vein grafts, 
arm-GSV composite grafts, and arm-arm composite 
vein grafts. Thirty-four grafts (17%) were con- 
structed predominantly of lesser saphenous vein 
(LSV), including single-segment LSV grafts, LSV- 
GSV composite vein grafts, and LSV-LSV compos- 
ite vein grafts. 
The inflow vessel for the autogenous bypass grafts 
was at the common femoral artery in 125 (58.7%), 
the deep femoral artery in 10 (4.7%), the superficial 
femoral artery in 42 (19.7%), and the popliteal artery 
in 36 (16.9%) bypasses. The outflow vessel for the 
autogenous bypass grafts was the popliteal artery in 
73 cases (34.3%), including 22 (10.3%) above-knee 
and 51 (23.9%) below-knee popliteal bypasses. One 
hundred forty autogenous bypasses (65.7%) were to 
the infrapopliteal level, including eight tibioperoneal 
trunk bypasses (3.8%) and 132 tibial or pedal 
bypasses (61.9%). 
The 87 prosthetic grafts included 69 polytetra- 
fluoroethylene grafts, 16 umbilical vein grafts, and 
two Dacron grafts. The proximal anastomosis of the 
87 secondary prosthetic bypass grafts was the com- 
mon femoral artery in 79 cases (91.0%) and the 
superficial femoral artery in eight cases (9.0%). The 
outflow vessels included the above-knee popliteal 
artery in 34 cases (39.1%), the below-knee popliteal 
artery in 38 cases (43.7%), and the tibial vessels in 15 
cases (17.2%). 
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Table I. Graft characteristics of 213 
autogenous grafts 
No. % 
Conduits 
In situ GSV 24 11.3 
Nonreversed GSV 36 16.9 
Reversed GSV 61 28.6 
Composite GSV 12 5.6 
Arm vein 36 16.9 
Arm-GSV composite 9 4.2 
Arm-arm composite 1 .5 
LSV 21 9.9 
LSV-GSV composite 12 5.6 
LSV-LSV composite I .5 
Inflow artery 
Common femoral I25 58.7 
Deep femoral i0 4.7 
Superficial femoral 42 19.7 
Popliteal 36 16.9 
Outflow artery 
Above-knee popliteal 22 10.3 
Below-knee poplitcal 51 23.9 
Tibioperoneal trunk 8 3.8 
Anterior final 36 16.9 
Posterior final 48 22.5 
Peroneal 40 18.8 
Dorsal pedal 8 3.8 
All surgical procedures were performed by a team 
consisting of a staff vascular surgeon and a vascular 
surgery fellow or senior resident. Standard intraop- 
erative techniques as described previously were em- 
ployed, including routine use of heparin, loupe 
magnification, and intraoperative angiography. 3'~°'18 
Whenever possible, vascular dissection and exposure 
was carried out in new tissue planes that were not 
violated during previous surgery. This involved 
careful selection of alternative inflow and outflow 
sites either proximal or distal to previous anasto- 
moses. The use of distally based, shorter grafts was 
preferred whenever possible to facilitate completion 
of the graft with autogenous vein, which was often in 
short supply. When GSV was not available, we have 
recently used the duplex scanner before surgery to 
assess the arm vein and LSV. This has greatly 
expedited the harvest of optimal-quality ectopic vein 
for secondary bypass. 
The mean follow-up of patients was 29 months 
(range 1 to 207 months), with complete follow-up 
available in 284 grafts (94.7%) and only 16 grafts lost 
to follow-up. To examine trends in secondary infrain- 
guinal bypass over time, the series was divided into 
two intervals: January 1975 to December 1984 and 
January 1985 to November 1993. The latter period 
corresponds to the interval in which a policy of clear 
preference for an all-autogenous vascular econstruc- 
tion was used. 18'19 This preference is reflected by 
Table II. Graft characteristic of 87 
prosthetic grafts 
No. % 
Conduits 
PTFE 69 7 
Umbilical vein 16 18 
Dacron 2 5 
Inflow artery 
Common femoral 79 91 
Superficial femoral 8 9 
Outflow artery 
Above-knee popliteal 34 39 
Below-knee popliteal 38 44 
Tibial vessels 15 17 
the fact that 71 of the secondary reconstructions 
performed with prosthetic grafts (82%) were com- 
pleted before 1985, whereas only 16 (18%) were 
completed after 1985. The results of secondary 
surgery were stratified by indication for surgery, 
outflow level, and type of venous conduit. To reflect 
contemporary results, the comparisons were re- 
stricted to vein grafts completed uring the 1985 
to 1993 interval, whenever there was a sufficient 
number of grafts in the stratified groups. The results 
of secondary autogenous bypass grafts obtained 
during the January 1985 to November 1993 in- 
terval were also compared with those obtained with 
435 primary autogenous bypass grafts completed 
during the same interval on our vascular surgery 
service. 
Primary patcncy refers to continuously patent 
bypass grafts that have not been manipulated in any 
way. Secondary patency includes grafts that have 
been patent continuously but have required various 
revisions including patch angioplasties, interposition, 
and "jump" graft extensions. Secondary patency also 
includes the few grafts that were reopened success- 
fully with thrombectomy or thrombolysis and sub- 
sequently revised. The difference between primary 
and secondary patency rates, however, is accounted 
for mainly by graft revisions resulting from our graft 
surveillance protocol. 
All the data included in this study have been 
collected prospectively since January 1975 in a 
computer-based vascular surgery database (Informix- 
SQL Relational Database for UNIX/DOS operating 
systems; Informix, Menlo Park, Calif.). Standard 
error estimates for the life tables were calculated 
according to the Greenwood method and compari- 
sons between life-table patency rates are by the 
Mantel-Cox log rank test of significance (with 
p _ 0.05 considered statistically significant) with the 
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BMPD statistical software package for personal 
computers (Los Angeles, Calif), 20'21 
RESULTS 
Morbidity and mortality rates. The periopera- 
tive morbidity rates for the 300 secondary infrain- 
guinal bypasses are shown in Table III. The total 
morbidity rate was 25%. Major cardiac morbidity 
included five myocardial infarctions (1.7%) and six 
instances of severe congestive heart failure requiring 
transfer to the intensive care unit for hemodynamic 
monitoring (2%). There were 20 significant wound 
complications (requiring reoperation or significantly 
prolonging hospitalization) including 12 infections 
(4%) and eight hematomas/seromas (2.7%). There 
were 53 early graft failures (17.7%) ( <_ 30 days after 
surgery) during the study, with 21 resulting in early 
amputations (7.0%). The early graft failure rate after 
autogenous grafts was 13.6% with a 5.6% early 
amputation rate, whereas the early failure rate after 
prosthetic grafts was 28.7% with a 10.3% early 
amputation rate. The single operative death in the 
series (0.3%) resulted from a myocardial infarction. 
Autogenous versus prosthetic secondary by- 
pass. The summary of the 5-year patenw, limb sal- 
vage, and patient survival rates for the entire series 
(1975 to 1993) is shown in Table IV. The 5-year 
primary patency rate for autogenous gra~s was sig- 
nificantly higher than that achieved with prosthetic 
grafts (43.2 _+ 4.6% vs 25.3% _+ 5.7%,p = 0.007). 
The 5-year secondary patency rate (Fig. 1) was also 
greater for autogenous grafts (51.5% _+ 4.6% vs 
27.4% _+ 6.1%; p < 0.001). The overall 5-year 
limb-salvage and 5-year survival rates were similar for 
patients undergoing autogenous versus prosthetic 
grafts. 
Early versus late failure of the primary by- 
pass. Patients whose primary bypass graft failed and 
required autogenous econdary bypass within 3 
months of the original operation are compared with 
those who suffered failure of the primary bypass be- 
yond 3 months in Table IV and Fig. 2. The secondaw 
bypasses performed in patients who suffered early 
primary graft failure fared significantly worse. The 
4-year primary and secondary patency rates in this 
subgroup were only 27.2% _+ 7.7% and 29.8% _+ 
8.3%, respectively. The 4-year limb-salvage rate after 
secondary bypass was only 43.9% +_ 10%. 
Autogenous vein secondary bypass: 1975 to 
1984 versus 1985 to 1993. The comparative r sults 
achieved with secondary autogenous vein bypasses in 
the first half versus the second half of the series are 
demonstrated in Table IV. Tables V and VI and 
Table III. Perioperative morbidity and 
mortality rates in 300 consecutive s condary 
infrainguinal bypasses 
No. % 
Mortality 
Fatal myocardial nfarction 1 0.3 
Morbidity 
Myocardial infarction 5 1.7 
Congestive h art failure 6 2 
Arrhythmia 23 7.7 
Renal failure 7 2.3 
Transient ischemic attack 1 0.3 
Pneumonia (by culture and x-ray) 4 1.3 
Graft infection 2 0.7 
Wound infection 12 4 
Hematoma 8 2.6 
Coagulopathy 2 0.7 
Gastrointestinal bleed 1_ 0.3 
Liver failure 1 0.3 
Deep venous thrombosis 1 0.3 
Pulmonary embolus 2 0.3 
Total 75 25 
Early graft failure 
Autogenous: 30-day amputation 29 13.6 
12 5.6 
25 28.7 
9 10.3 
Prosthetic: 30-day amputation 
Fig. 3 show the secondary patency life tables for 
the two intervals and demonstrate the improve- 
ment achieved in the 1985 to 1993 interval 
(59.1% +_ 5.8% vs 38.3% + 6.9% at 5 years, 
p = 0.017). 
Popliteal versus tibial outflow level. The com- 
parativc results of secondary autogenous bypass 
grafts to the tibia] versus popliteat outflow level for 
the 1985 to 1993 interval are shown in Table IV. 
There were no significant differences in the 5-year 
patency or limb-salvage rates. The secondary life- 
table patency rates for the two outflow levels are 
shown graphically in Fig. 4. 
GSV versus alternative vein bypass. The results 
of GSV secondary bypasses (including in situ, 
reversed, and nonreversed translocated veins with 
lysed valves) are compared with those of alternative- 
vein secondary bypasses (including composite, arm 
vein, and LSV grafts) for the 1985 to 1993 interval 
in Table IV. The 5-year primary patency rates for 
GSV bypasses were superior to those obtained with 
alternative veins (60.4% -+ 7.1% vs 35% + 11%, 
p = 0.026). Similarly, as demonstrated in Fig. 5, the 
5-year secondary patency rates for GSV grafts 
showed a similar trend toward superiority over 
alternative-vein grafts (68.5% -+ 6.0% vs 48.3% - 
10.5%; p < 0.09). The 5-year limb-salvage rate 
accomplished with GSV was also superior compared 
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Fig. 1. Life-table analysis of secondary patency rates of secondary autogenous vein grafts vs 
prosthetic bypass grafts. 
with alternative veins (77.8% -+ 7.4% vs 54.2% + 
11.8%;p < 0.046). 
Arm vein versus LSV. In patients who lack 
sufficient ipsilateral and contralateral GSV, autog- 
enous conduits are often constructed with either arm 
vein or LSV. The 4-year patency and limb-salvage 
rates of secondary bypasses constructed with arm vein 
are compared with those constructed with LSV in 
Table IV, which demonstrates no significant differ- 
ences in primary, secondary, or limb-salvage rates. 
Limb salvage versus claudication. The results of 
secondary autogenous bypass performed for claudi- 
cation are compared with those performed for limb 
salvage during the 1985 to 1993 interval in Table IV. 
The 5-year patency rate of secondary bypasses 
performed for claudication (75.8% - 8.1%) was 
superior to that achieved with bypasses performed for 
limb salvage (52.3% -+ 7.9%; p = 0.048), with 
similar trends of superiority noted in primary patency 
rate, limb-loss rate, and patient survival rates. The 
secondary patency curves for bypasses performed for 
claudication versus limb salvage are illustrated in 
Fig. 6. 
Secondary versus primary autogenous recon- 
structions. The 5-year patency and limb salvage 
results obtained with secondary autogenous bypass 
grafts in this study during the 1985 to 1993 interval 
are compared with the results achieved with 435 
primary autogenous bypass grafts during the same 
interval in Table IV. The 5-year primary patency, 
secondary patency, and limb-salvage rates were 
superior for primary bypasses compared with sec- 
ondary bypasses. The 5-year patient survival rates did 
not differ. The secondary patency rates for secondary 
versus primary bypasses are compared in Fig. 7. 
DISCUSSION 
Failure of an infraingulnal bypass graft presents a 
major challenge to the vascular surgeon. The correct 
management i  any particular patient varies with a 
number of fundamental considerations. Most impor- 
tant is the functional status of the patient and the 
condition of the affected extremity. A significant 
proportion of patients will appear well compensated 
after graft thrombosis, with relatively mild disability 
not warranting intervention. Similarly, patients 
whose general health status has declined to the point 
where active ambulation is no longer realistic may 
benefit most from simple observation. The majority 
of patients who were originally operated on for severe 
ischemia, however, will suffer recurrent limb- 
threatening ischemia or severe disability from symp- 
toms ofclaudication at the time of graft failure. These 
patients require revascularization for limb preserva- 
tion and maintenance of independent function. 
Unfortunately, restoration of durable patency to 
failed infrainguinal grafts has generally not been 
attainable. Thrombectomy and revision of throm- 
bosed grafts has resulted in patency rates of only 19% 
to 28% at the 5-year interval for the failed vein 
grafts. 7,8 The long-term results after thrombectomy 
of polytetrafluoroethylene grafts have been even 
poorer, with patency rates of 32% at 21/2 years and 
11% at 5 years.9a° Thrombolysis of occluded infrain- 
guinal bypass grafts followed by graft revision has 
also resulted in low patency rates of 0% to 37% 1 to 
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Fig. 2. Life-table analysis of secondary patency rates of autogenous vein secondary bypass 
grafts after early primary bypass graft failure (< 3 months) vs late primary bypass graft failure 
( < 3 months). 
3 years after treatment for both prosthetic and vein 
conduits, u13 In our experience, thrombectomy or
thrombolysis of failed infrainguinal grafts represents 
a temporizing measure, with the majority of patients 
requiring an ongoing series of reintcrventions to
maintain graft patency. Thus we believe that the 
majority of patients with failed infralnguinal bypass 
grafts and recurrcnt ischemia should bc treated with 
an entirely new secondary bypass graft. Thrombec- 
tomy and thrombolysis of occluded grafts on our 
service are reserved for selected cases based on the 
timing of graft occlusion, the condition of the 
original conduit, and the complete absence of autog- 
enous, including ectopic, veiny 
Given our commitment to a new bypass graft as 
the preferred mode of revascularization after infrain- 
guinal graft failure, and the historically inferior 
results of secondary bypass compared with primary 
bypass, we undertook this review to determine the 
preferred strategies for and current results of reop- 
erative bypass. 
In 1985 we established a clear preference on our 
vascular surgery service for the use of autogenous 
vein as the conduit of choice for all infrainguinal 
bypass procedures. Thus our experience with pros- 
thetic conduits for secondary bypass is largely con- 
centrated (82%) in the 1975 to 1984 interval. This 
preference fbr the routine application of autogenous 
vein introduces a potential bias against he results 
obtained with prosthetic grafts, and caution must 
therefore be applied in generalizing from the results 
obtained. Nonetheless, the operative techniques, ma- 
terials, and procedures used with prosthetic grafts 
have been relatively constant and the superiority, of 
autogenous grafts over prosthetic grafts identified in 
this series would likely persist in a modern concurrent 
series. The 27.4% 3-year secondary patency rate 
achieved with prosthetic grafts in this series is inferior 
to the results reported by Yang et aI.17 who achieved a 
38% 4-year primary and 55% 4-year secondary pa- 
tency rate in a series of 73 reoperative polytetrafluo- 
roethylene grafts. Other authors, however, have re- 
ported poor results imilar to ours for secondai T by- 
pass with prosthetic graft. Quifiones-Baldrich etal. 9 
noted a 30% 21/2-year patency rate for reoperative 
polytetrafluoroethylene bypasses compared with a 
55% 2V2-year patency rate with reoperative vein 
grafts. Bartlett et al. is achieved a 32% 5-year second- 
ary patency rate in a series composed of 87% reopera- 
tive polytetrafluoroethylene grafts, with many pa- 
tients requiring multiple reinterventions. Thus we 
believe that autogenous vein should be employed for 
secondary bypass whenever possible. The occasional. 
patient with reconstitution of the above-lmee 
popliteal artery with good runoff may be treated ef- 
fectively with a prosthetic graft. In our experience, 
however, patients with recurrent ischemia or severe 
claudication after infrainguinal graft failure seldom 
have the anatomy conducive to a prosthetic bypass. 
In contrast to prosthetic grafting, our techniques 
for bypass with autogenous vein have evolved uring 
the study interval. Technical improvements in our 
ability to operate on smaller and more distal outflow 
vessels, the application of in situ and nonreversed vein 
grafts, alternative strategies for arterial exposure, and 
avoidance of previously dissected and scarred vessels 
JOURNAL OF VASCULAR SURGERY 
288 Belkin et al. February 1995 
Table IV. Life-table analysis of secondary infrainguinal reconstruction 
Graft type or  
indication for No. of 5-Yr primary 5-Yr secondary 
surgery grafts patency (%) patency (%) 
5-Yr limb 5-Yr patient 
salvage (%) survival (%) 
Prosthetic grafts 87 25.3 _+ 5.7 27.4 + 6.1 
Autogenous grafts 213 43.2 _+ 4.6 51.5 - 4.6 
p Value 0.007 < 0.001 
Early primary graft failure 44 27.2 _+ 7.7* 29.8 -+ 8.3* 
Late primary graft failure 169 51.5 -+ 4.9* 61.1 + 4.7* 
p Value 0.017 0.003 
Autogenous bypass 1975-1984 59 28.8 + 6.3 38.3 _+ 6.9 
Autogenous bypass 1985-1993 154 49.5 _+ 6.3 59.1 -+ 5.8 
p Value 0.01 0.017 
Popllteal outflow 43 44.5 + 9.7 53.8 + 9.4 
Tibia] outflow 111 51.4 + 8.1 60.9 _+ 7.4 
p Value 0.295 0.281 
GSVt 79 60.4 _+ 7.1 68.5 + 6.0 
Alternative veins 75 35.0 +- 11.0 48.3 -+ 10.5 
p Value 0.020 0.090 
Arm vein§ 46 46.4 + 9.2* 56.5 -+ 8.1" 
LSV[[ 34 54.7 + 9.9* 54.7 + 9.9* 
p Value 0.268 0.417 
Claudication 35 63.8 + 9.2 75.8 + 8.1 
Limb salvage 178 45.1 -+ 7.7 52.3 -+ 7.9 
p Value 0.079 0.048 
Primary autogenous bypass 435 65.1 + 4.2 79.7 + 3.3 
Secondary autogenous bypass 154 49.5 + 6.3 59.1 -+ 5.8 
p Value 0.020 < 0.001 
53.5 -+ 7.5 71.5 _+ 6.7 
58.7 + 5.5 72.6 + 4.7 
0.23 0.45 
43.9 -+ 10" 81.4 -+ 10.7" 
74.9 +- 4.4* 75.2 _+ 4.6* 
0.004 0.3 
40.4 _+ 7.6 73.8 + 7.6 
72.4 + 6.6 74.4 -+ 4.8 
< 0.001 0.24 
62.8 + 12.5 NAt 
78.2 + 5.7 NAt 
0.174 
77.8 -+ 7.4 NAt 
54.2 _+ 11.8 NA ~ 
0.046 
65.4 _+ 8.0* NAt 
55.0 -+ 14.1" NAt 
0.261 
87.4 _+ 7.1 85.2 _+ 6.9 
66.6 -+ 9.5 72.8 _+ 5.5 
0.056 0.09 
91.3 _+ 4.3 75.1 _+ 4.3 
72.4 _+ 6.6 74.4 _+ 4.8 
0.003 0.456 
NA, Not applicable for comparison. 
*Follow-up interval is 4 years for these groups. 
tGSV grafts include in situ, nonreversed, translocated, and reversed grafts. 
:~Alternative ein grafts include arm vein grafts, LSV grafts, and composite vein grafts. 
§Includes arm vein and arm vein composite vein grafts. 
[[Includes LSV and LSV composite vein grafts. 
Tab le  V.  Secondary  patency rates o f  reoperat ive autogenous  bypasses per fo rmed f rom 1975 
to 1984 
No. of No. of No. of No. of Interval In terva l  Cumulat ive Standard 
Interval grafts grafts limbs grafts failure patency patency error 
(mo) at risk failing lost  withdrawn (%) (%) (%) (%) 
0-1 59 11 0 2 19.0 81.0 81.0 5.1 
1-3 46 7 1 1 15.0 85.0 68.8 6.1 
3-6 37 6 0 2 16.7 83.3 57.4 6.7 
6-12 29 3 0 0 10.3 89.7 51.4 6.8 
12-24 26 3 0 1 11.8 88.2 45.4 6.8 
24-36 22 0 0 1 0 100 45.4 6.8 
36-48 21 2 0 2 10.0 90.0 40.8 6.9 
48-60 17 1 0 2 6.2 93.8 38.3 6.9 
(part icular ly at the out f low level) have cont r ibuted  to 
enhanced results. Table  IV  demonst rates  the marked  
advances that have been attained in pr imary,  second- 
ary, and l imb-salvage rates w i th  secondary autog-  
enous bypass grafts f rom the 1975 to 1984 to the 
1985 to 1993 intervals. The  59 .1% 5-year secondary 
patency rate and 72 .4% l imb-salvage rate represent  a
signif icant advance over  the results we  repor ted  in 
1980,  where  secondary patency rates o f  37% and 
l imb-salvage rates o f  50% were attained, a The  
patency rates we  achieved are similar to those in the 
recent  repor t  o f  Edwards  et al., 14 who atta ined a 71% 
5-year secondary patency rate in a series o f  103 
secondary bypasses. 
A l though it has tradit ional ly been bel ieved that 
t ib iaMevel  out f low grafts have lower  patency rates 
than those to the popl i teal  level, secondary tibial 
bypass grafts in this series fared at least as wel l  as those 
to the popl i teal  evel (Table IV) .  This  is similar to the 
exper ience o f  Edwards  et al., 14 as wel l  as our  
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Fig. 3. Life-table analysis of secondary patency rates of autogenous vein secondary bypass 
grafts performed in 1975-1984 time interval vs 1985-1993 time interval. 
Table VI. Secondary patency rates of reoperative autogenous bypasses performed from 1985 
to 1993 
No. of No. of No. of No. of Interval Interval Cumulative Standard 
Interval grafts grafts limbs grafts failure patency patency error 
(too) at risk failing los t  withdrawn (%) (%) (%) (%) 
0-1 154 15 2 4 9.9 90.i 90.1 2.4 
1-3 133 9 1 6 6.9 93.1 83.9 3.0 
3-6 117 9 0 8 8.0 92.0 77.2 3.5 
6-12 100 3 0 23 3.4 96.6 74.5 3.7 
12-24 74 7 0 21 11.0 89.0 66.3 4.4 
24-36 46 2 0 13 5.1 94.9 63.0 4,8 
36-48 31 0 0 11 0 100 63.0 4.8 
48-60 20 1 0 7 6.1 93.9 59.1 5.8 
previously reported experience with primary in situ 
bypass grafts. 3Thus selection of the outflow level for 
a given bypass hould be based on the available length 
of autogenous vein and the angiographic appearance 
of the outflow vessels without regard to how far 
distally the anastomosis must be located. 
Many patients who have graft failure will not have 
ipsilateral or contralateral GSV available for second- 
ary bypass. In this series (1985 to 1993), 49% of 
secondary autogenous reconstructions were com- 
pleted with some alternative to GSV including arm 
vein, LSV, or an autogenous composite vein graft. As 
anticipated, the results achieved (Table IV) were in- 
ferior to those attained with GSV. The 48.3% 5-year 
secondary patency and 54.2% 5-year limb-salvage 
rates for alternative in grafts are suboptimal but not 
surprising iven the complex nature of these reopera- 
tive cases. In an effort to determine the best al- 
ternative conduit to GVS, we compared the re- 
suits achieved with arm vein to those with LSV 
(Table IV). In our experience the results are similar, 
with a 56.5% secondary patency rate and 65.4% 
limb-salvage rate at 4 years for arm vein compared 
with a 54.7% secondary patency and 55.0% limb- 
salvage rate for LSV. These results are similar to those 
reported previously. Harward et al. 23 reported on a 
series of 43 inffainguinal rm vein bypasses including 
49% secondary bypasses. They attained a 66% sec- 
ondary patency and 63% limb-salvage rate 2 years 
after surgery. Andros et al. 24 reported on 80 patients 
who underwent single-segment arm vein bypasses, 
including 30 (34%) who underwent secondary pro- 
cedures. Noteworthy were the superior esults ob- 
tained with primary arm vein bypass (68% 5-year 
secondary patency rate) compared with secondary 
arm vein bypass (62% 2-year secondary, patency rate), 
again demonstrating the complexity of reoperative 
inffainguinal surgery. Fewer reports have evaluated 
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LSV as an alternative conduit for infrainguinal by- 
pass. Chang et al. 2s attained a 55% 3-year primary 
patency rate in their experience with 69 infrainguinal 
bypasses with LSV including 73% secondary by- 
passes. Based on our experience and that of others, we 
believe that arm vein and LSV are equally suitable 
conduits for secondary bypass in the absence of GSV. 
When we anticipate the need for alternative vein be- 
fore surgery, patients undergo comprehensive nous 
mapping of the basilic and cephalic veins and LSVs to 
identify the best available vein conduit. When GSV is 
unavailable and the alternative veins are limited in 
quality or quantity, the use of prosthetic grafts may 
be preferable. Absence of visible veins or multiple 
venipunctures in the forearms have no relationship to 
the upper arm veins, which may be of excellent caliber 
and quality. The particular advantages and disadvan- 
tages of arm vein versus LSV have been reviewed 
previously. 26 
The indication for surgery was severe claudication 
in 16.5% of patients in this series. Careful review of 
the results in this subgroup is important to justify the 
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somewhat aggressive course of reoperative proce- 
dures in the absence of frank, limb-threatening 
ischemia. As shown in Table IV, the 75.8% 5-year 
secondary patency, 12.6% 5-year limb-loss, and 
85.2% 5-year survival rates achieved in this subgroup 
of patients with severe claudication were superior to 
those obtained in patients operated on for limb 
salvage and seem to justify intervention by traditional 
criteria. Nonetheless, the majority of patients who 
have claudication after primary bypass graft failure 
may not warrant intervention. The decision to 
intervene must be based on a careful evaluation of the 
patients' disability, hemodynamic status, and func- 
tional status and the availability of autogenous 
conduit. 
When the results in this series of secondary 
bypasses were compared with those we have attained 
in our series of primary bypasses (Table IV), primary 
bypasses were found to have superior patency and 
limb-salvage rates. This result is not surprising and 
has been noted by others. 14 Aside from. the increased 
reliance on conduits other than intact GSV and the 
increased complexit T of the operations, a number of 
other factors may contribute to the inferior results of 
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secondary bypass. By definition, patients requiring 
secondary bypass have had failed previous infrain- 
guinal reconstructions and therefore will tend to 
include those patients who have more severe ath- 
erosclerosis, those who form more virulent intimal 
hyperplasia, those with hypercoagulable states, and 
those with small or poor-quality autogenous vein. 
These factors may have contributed to the early 
failure of the primary bypass graft and place the 
second graft at risk. The extremely poor results of 
secondary bypass after early failure ( < 3 months) of 
the primary bypass (Table IV) reflect the challeng- 
ing qualities of these patients. Despite these del- 
eterious factors, which are admittedly difficult to 
quantify, the results of this and other recent series 
show continued improvement in our ability to 
revascularize and preserve limbs safely and success- 
fully in patients who have failed previous infrain- 
guinal reconstructions. These results stand in con- 
trast to those from previous series of secondary 
infrainguinal bypass in which results led some 
surgeons to suggest that primary amputation may 
be preferable in a significant proportion of patients 
after failure of primary bypass grafts. 27 Our results 
do not justify such a nihilistic recommendation. In 
a recent editorial, however, Skillman 28 raises an 
important issue about complex infrainguinal bypass 
in general and reoperative bypass in particular. He 
contends that the traditional criteria of "success" 
after distal bypass including graft patency and limb 
salvage are insufficient parameters on which to 
evaluate the advisability of surgery. Many of our 
patients are subjected to multiple interventions as- 
sociated with significant pain, disability, and long- 
term rehabilitation. The presence of a patent bypass 
graft in a painful, swollen limb on a patient who 
is unable to work or function in society is difficult 
to call a "success." Although we continue to believe 
that the majority of our patients benefit from 
aggressive attempts at limb salvage, it is important 
for us to measure functional patient outcomes 
objectively after limb-salvage surgery, with greater 
emphasis placed on physical function and comfort, 
role function, and general health perception. Only 
through objective evaluation of outcome, combin- 
ing traditional criteria (graft patency and limb 
salvage) with more broad measures of patient well- 
being, will we be able to determine who benefits 
most from our interventions. 
We gratefully acknowledge the data management 
assistance of Ms. Julie Lombara. 
REFERENCES 
1. Brewster DC, LaSalle AJ, Robison JG, et ai. Femoropopliteal 
graft failures: clinical consequences and success of secondary 
reconstructions. Arch Surg 1984;118:1043-50. 
2. Rutherford RB, Jones DN, Bergentz S, et al. The efficacy of 
dextran 40 in preventing early postoperative thrombosis 
following difficult lower extremity bypass. J VASC SURG 
1984; 1:765 -71. 
3. Donaldson MC, Mannick JA, Whittemore AD. Femoral- 
distal bypass with in situ greater saphenous vein: long term 
results using the Mills valvulatome. Ann Surg 1991;213:457- 
65. 
4. Leather KP, Shah DJ, Chang BB, et al. Resurrection ofthe in 
situ saphenous vein bypass: 1000 cases later. Ann Surg 
1988;208:435-42. 
5. Taylor LM, Edwards JM, Porter JM. Present status of reversed 
vein bypass grafting: five year results of a modern series. 
J VASC SURG 1990;11:193-206. 
6. Donaldson MC, Mannick JA, Whittemore AD. Causes of 
primary graft failure after in situ saphenous vein bypass 
grafting. J VASC SURG 1992;15:113-20. 
7. Cohen JR, Mannick JA, Couch NP, et al. Recognition and 
management of impending vein graft failure. Arch Surg 
1986;121:758-9. 
8. Whittemore AD, Clowes AW, Couch NP, et ai. Secondary 
femoropopliteal reconstruction. Ann Surg 1981;193:35-42. 
9. Qnifiones-Baldrich WJ, Prego A, Ucelay-Gomez R, et al. 
Failure of PTFE infrainguinal revascularization: patterns, 
management alternatives and outcome. Ann Vasc Surg 
1991;5:163-9. 
10. Whittemore AD, Kent CK, Donaldson MC, et al. What is the 
role of polytetrafluoroethylene grafts in infrainguinal recon- 
struction? J VAsc SURG 1989;10:299-305. 
11. Belkin M, Donaldson MC, Whittemore AD, et al. Observa- 
tions on the use of thrombolytic agents for thrombotic 
occlusions of infrainguinal vein grafts. J VAsc SURG 1990; 
11:289-96. 
12. Graor RA, Risus B, Young JR, et al. Thrombolysis of 
peripheral arterial bypass grafts: surgical thrombectomy 
compared with thrombolysis. J Vasc SURG 1988;7:347-55. 
13. Parent FN, Prowski JJ, Bernhard VM, et al. Outcome of 
intraarterial urokinase for acute vascular occlusion. J Cardio- 
vasc Surg 1991;32:680-90. 
14. Edwards JE, Taylor LM, Porter JM. Treatment offailed lower 
extremity bypass grafts with new autogenous vein bypass 
grafting. J VASC SURG 1990; 11:136-45. 
15. Bartlett ST, Olinde AJ, Flinn WR, et al. The reoperative 
potential of infrainguinal bypass: long-term limb and patient 
survival. J VASC SURG 1987;5:170-9. 
16. Ascer E, Collier P, Gupta SK, Veith FJ. Reoperation for 
polytetrafluoroethylene bypass failure: the importance of 
distal outflow site and operative technique in determining 
outcome. J VASC SUV, G 1987;5:298-310. 
17. Yang PM, Wengerter KR, Veith FJ, et al. Value and 
limitations of secondary femoropopliteal bypasses with poly- 
tettattuoroethylene. J VAsc SUI',G 1991;14:292-8. 
18. Donaldson MC, Whittemore AD, Mannick JA, Further 
experience with an all-autogenous ti sue policy for infrain- 
guinal reconstruction. J VASC SURG 1993;18:41-8. 
19. Kent KC, Whittemore AD, Mannick JA. Short-term and 
mid-term results with an all-autogenous ti sue policy for 
infrainguinal reconstruction. J VAsc SURG 1989;9:107-14. 
20. Greenwood M. The natural duration of cancer. In: Reports on 
JOURNAL OF VASCULAR SURGERY 
Volume 21, Number 2 Belkin et aL 293 
public health and medical subjects, no. 33: London: His 
Majesty's Stationary Office, 1926. 
21. Mantel N. Evaluation of survival data and two new rank order 
statistics arising in its consideration. Cancer Chemother Pep 
1966;50:163-70. 
22. Belkin M. Thrombolytic therapy for arterial occlusive disease. 
Adv Vasc Surg 1993;1:189-211. 
23. Harward TRS, Coe D, Flynn TC, Seeger JIM. The use of arm 
vein conduits during infrageniculate arterial bypass. J VASC 
SURG 1992;16:420-7. 
24. Andros G, Harris RW, Salles-Cunha SX, et al. Arm veins for 
arterial revascularization of the leg: arteriographic and clinical 
observations. J VASC SURG 1986;4:416-27. 
25. Chang BB, Paty PSK, Shah DM, Leather RP. The lesser 
saphenous vein: an underappreciated source of autogenous 
vein. J VASC SURG 1992;15:152-7. 
26. Belkin M, Whittemore AD. Reoperative distal bypass surgery. 
Semin Vase Surg (in press). 
27. Dennis JW, Littooy FN, Greisler HP, Baker WH. Secondary 
vascular procedures with polytetrafluoroethylene grafts for 
lower extremity ischemia na male veteran population. J VASe 
SURG 1988;8:137-42. 
28. Skillman JJ. It can be fixed, but should it be? Ann Surg 
1993;218:713-4. 
Submitted June 10, 1994; accepted Sept. 23, 1994. 
DISCUSSION 
Dr. Enrico Ascer (Brooklyn, N.Y.). I am in agreement 
that a lifelong commitment between the patient and the 
vascular surgeon is initiated when an arterial bypass for 
limb salvage is performed. You have subscribed to this 
concept and are to be commended for reporting acomplete 
follow-up in 95% of your patients during the past 19 years. 
Today you shared with us some of the lessons you learned 
with the management of 300 secondary infrainguinal 
reconstructions. You clearly reconfirmed the fact that grafts 
constructed with autogenous veins performed better than 
polytetrafluoroethylene grafts, and sufficient lengths of 
autogenous veins can be harvested in a large proportion of 
patients ubjected to redo operations. For this you have not 
hesitated to reach for ectopic superficial veins in the arm or 
contralateral lower extremity. 
However, I was somewhat surprised to find out that 
you averaged less than two tertiary operations per year and, 
because this observation is in disagreement with our own 
experience and that of others, would you define more 
clearly our criteria for performing secondary amputations. 
Because it is reasonable to assume that the availability of 
autogenous vein grafts is inversely proportional to the 
number of reoperations, would you consider performing 
secondary infrapopliteal bypass with prosthetic material 
with adjunctive distal vein patches or arteriovenous fi tulas ?
I believe that the time has come to address prospectively the 
potential role of these newer strategies, particularly in face 
of the limited primary patency result obtained with 
alternative veins of only 35% at 5 years in this study. 
Based on your findings regarding alternative veins, 
what segment of vein would you preferentially use, 
assuming they were all available, and why? 
Could you also describe the specific factors leading to 
a high failure rate for alternative vein grafts. 
You have previously reported on the value of screening 
for hypercoagulable disorders. Because in the setting of 
redo surgery this may assume an even greater significance, 
not only in terms of the potential need for pharmacologic 
manipulation but also for the comparison ofpatency results 
among the various types of grafts, I would suggest that this 
information be added to the article. 
The 5-year primary patency rate of secondary vein 
bypasses was significantly better in the latter part of the 
study. In your opinion, what was the single most important 
reason accounting for this improvement? Did you notice 
similar trends in your primary vein bypasses during 
comparable intervals? 
The overall results are convincing enough that they can 
be used, and they should be used to inhibit those who have 
been vocal against limb-salvage attempts in favor of major 
amputations after failure of the primary operation. Form- 
nately, these objections are not usually raised by vascular 
surgeons. On the other hand, those of us -who eagerly and 
painfully follow a policy of aggressive limb salvage should 
continue in our quest for better esults. Without a doubt, 
the work presented today is a step in the right direction. 
Dr. Michael Belkin. As you point out, there was a 
relatively small number of tertiary or more reoperations in
our series. Although I would like to tell you that we do few 
tertiary operations because our results with primary and 
secondary operations are so good, I think a more realistic 
explanation is that we failed to identify that some of our 
operations were in fact tertiary. This is especially likely in 
those patients who were referred to our institution from the 
outside, where the details of their previous vascular history 
were sketchy. 
The hypothetical question of what should be done in 
the absence of available autogenous vein frequently comes 
up. It is largely a hypothetical question because in the vast 
majority of circumstances sufficient autogenous vein can be 
found to perform reoperative bypass. Use of a combination 
of ingenuity in the design of the operation and preoperative 
duplex scanning to evaluate ctopic vein greatly facilitates 
the completion of the operation. In those few patients in 
whom autogenous vein is not available, a number of 
strategies you proposed might be useful. We do not, 
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however, have any significant experience with the use of 
inftapopliteal prosthetic bypass grafts with either distal vein 
patches or arteriovenous fistulas. 
The question as to which alternative vein serves as the 
best conduit has frequently been debated on our own 
service. My own bias has been that arm veins serve as the 
best alternative conduit, whereas my parmers have thought 
that the lesser saphenous vein was superior. The results of 
this study, however, confrm that both conduits work 
equally well. The important message is to use the best 
available conduit in the given patient based on preoperative 
duplex scanning and intraoperative exploration. 
Dr. Ascer inquired, "what is the mechanism of failure 
of these reoperative bypass grafts." I am not sure that the 
mechanism of failure in these reoperative bypass grafts 
differs in any significant way from the mechanism of failure 
in primary bypass grafts. Nonetheless, our reliance on 
ectopic and composite vein grafts undoubtedly places these 
grafts at high risk for complications. We have identified, for 
example, that approximately 30% of our composite vein 
grafts ultimately develop significant stenoses at the site of 
venovenostomy, requiring intervention. These and other 
problems emphasize the need for aggressive postoperative 
graft surveillance with a duplex scan to identify stenotic 
lesions, allowing their repair before graft failure. We believe 
that the results we achieve with ectopic and composite vein 
grafts will improve over time as the impact of our 
aggressive surveillance regimen becomes manifest. 
Finally, Dr. Ascer asked what is the most important 
factor that has led to the improvements in results identified 
in this study over time. Although it is difficult to single out 
one particular factor, I would guess that it is the improved 
quality of the autogenous vein conduits we have employed. 
Factors contributing to this improvement include the use 
of the duplex scan and improved techniques in harvesting 
and preparing the conduit. 
Dr. John M. Porter (Portland, Ore.). Do you have any 
observations or thoughts about the dramatic patient 
survival rates in these redo operations! I noted a 72% to 
75% 5-year survival rate, and a large majority of patients 
were undergoing operation for limb salvage, in fact redo 
operations. Your 5-year survival rate is equal to everyone 
else's claudication 5-year survival rate in first-time opera- 
tions. I am impressed by this dramatic survival rate and I 
believe that Boston is the place to undergo a redo 
operation. 
Dr. Belkin. I think the survival rate was superior to 
what we expected. Compared with your own series of 
reoperative bypass, there was a dramatic improvement. I 
would submit o you, however, that the 5-year survival rate 
of 12% that you noted in that study was probably more of 
an aberration from what has been recorded in the literature 
than what we have reported here today. 
Dr. Porter. I believe 75% is an equal aberration. 
Dr. Belkin. That may be true, but even your own more 
recent series of tertiary bypass identified a much more 
favorable survival rate of 68% at 4 years. All of our patients 
are followed up very closely by our vascular medicine 
service and cardiologists and many of them are subjected to 
long-term cardiac risk-modification programs. I believe 
that it is realistic for us to attempt to achieve survival rates 
approaching 70% at 5 years after reoperative bypass. 
Dr. George Andros (Burbank, Calif.). You have 
commendable overall ow mortality and 30-day mortality 
rates. It is better than what we observed in our series. 
However, we should look at the survival numbers. John's 
mortality figures are closer to yours than to ours. On redo 
operations, our survival rate is 40% to 50% at 5 years. I f  
you are correct hat the number is closer to 70%, do you 
believe that there are implications regarding practice 
guidelines, possibly even a federally mandated policy about 
leg revascularizations, both primary and reoperative? If  the 
survival rate is 40%, perhaps one might justify being less 
aggressive. If, in fact, these people live as long as you 
suggest hey do, we may have to be more determined in 
taking Care of them and attempting to preserve their limbs. 
Dr. Belkin. I think we should point out that the 
average age of patients in this study was 65 years, and 
therefore a 70% 5-year survival rate is not surprising, I
cannot say what will happen with health policy, but I do 
believe that we are going to be forced to document our 
results in ways that are more sophisticated than what we 
have done in the past, Documentation ofoutcome analysis 
will be thrust on us and done for us if we do not do it 
ourselves. I believe that we must justify our results based on 
the patient's functional stares, physical and social fimction, 
and perception of general health. I think these are 
important avenues for furore research. 
Dr. Michael Sobel (Richmond, Va.). Your group, and 
in particular Dr. Donaldson, has shown a strong interest in 
the thrombotic tendency that some of these patients may 
have. What percentage of your patients with failed or 
failing grafts who underwent reoperation are subsequently 
treated with more intense antithrombotic or anticoagulant 
regimens? What role do you think that played in the 
extended urability of the repeat bypasses? 
Dr. Belldn. That is a good question. Nearly all of our 
patients who can tolerate aspirin are given an aspirin a day 
for life. We do use Coumadin selectively for patients in 
whom we believe the bypass graft is tenuous. The selection 
remains unscientific, however~ and is based on our subjec- 
tive feelings about the quality of the conduit and its 
outflow. I believe that there are ongoing prospective trials 
to evaluate which patients benefit from anticoagulation. 
Dr. Sobel. Do you routinely evaluate patients for 
predisposition to thrombosis once a graft has failed? 
Dr. Belkin. We have been evaluating all of our patients 
who undergo vascular surgery for hypercoagulable states as 
part of our research protocol. Our initial review docu- 
mented that those patients with hypercoagulable states had 
a higher predisposition to graft failure. In this series, 
however, when investigated, hypercoagulable states were 
not identified in the majority of patients with failed vein 
grafts. 
Dr. Benjamin Chang (Albany, N.Y.). It seemed that 
according to your data bypasses completed with a single 
segment of autogenous vein performed much better than 
bypasses completed with spliced vein, and that difference 
seems to be between our data and Dr. Porter's data 
compared with yours. Do you have any comments on that? 
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Also, it seemed that the limb-salvage rate you obtained 
in the limb-salvage group at 5 years was approximately 
72%, which, relatively speaking, is low. Do you have any 
comments as to the reasons for that? 
Finally, in the group with claudication, the limb-loss 
rate at 5 years was about 13%, which, compared with the 
natural history of this disease, is high. Would that make you 
cautious in offering patients with claudication reoperations 
at this point? 
Dr. Belldn. Composite vein grafts are more compli- 
cated than single-segment bypass grafts. The avoidance of 
subsequent problems after the venovenostomy is aproblem 
we have not yet conquered. As I mentioned earlier, 
however, I am hopeful that increasingly aggressive surveil- 
lance regimens will allow us to identify these problems 
before graft failure. The 72% 5-year limb salvage rate is 
lower than what has been reported historically in series of 
primary bypass. Nonetheless, many of these patients have 
complex problems and the reoperative surgery offers many 
challenges beyond those found in primary bypass. Al- 
though we will continue to try to improve our 5-year 
limb-salvage rates, I believe that the 72% salvage rate 
identified in this study is realistic. 
I think your point about the 13% 5-year limb-loss rate 
in patients with claudication isan important point. I do not 
believe, however, that the patients with claudication that 
we operated on with reoperative bypass are representative 
of patients with claudication in general. Although I am 
unable to quote you the exact hemodynamic status of these 
patients, I can assure you that for a patient to undergo 
reoperative bypass for clandication on our service, he or she 
must be severely disabled. I would venture aguess that the 
majority of these patients had hemodynamic parameters we 
would normally consider in the ischemic range. I therefore 
do not believe it is fair to compare this subgroup to the 
overall group of patients with claudication. I would suggest 
that a 13% limb-loss rate in these patients is similar or 
better than what would have been achieved with observa- 
tion alone. 
Dr. John H. N. Wolfe. (London, United Kingdom). 
These are obviously important and interesting data, but for 
each of us to use them properly, we have to be able to 
extrapolate them to our own practice. Your patients are 
younger than the ones we would see in London. They also 
live longer and a proportion of them have claudication. I 
leafed through a lot of data on this, but I think it was 62% 
of patients in whom one was able to use a single segment 
of autologous long saphenous vein, which, in my practice, 
would be unusual as a secondary procedure. I f  you look at 
patients with critical ischemia in whom patency rates and 
limb-salvage rates were lower, and you look at patients with 
critical ischemia in whom you are not able to use a single 
segment of autologous vein, I can compare your data with 
my own. What in that group might be y-our limb-salvage 
rates at 2 and 5 years? I suspect hat by putting in the 
patients with claudication and some of these other groups, 
it can make the data look a little better. 
Dr. Belkin. We have attempted to stratify our result in 
as many ways as possible such that vascular surgeons may 
be able to make sense of the data in reference to their own 
patients. Unfortunately, ou can divide the data in only so 
many ways before the numbers become too small to have 
any statistical impact. We would agree, however, that L~you 
were to combine the poor subgroups into one group, the 
results would be poorer. For example, patients operated on 
for limb salvage with ectopic omposite vein grafts after an 
early primary graft failure would be likely to do extremely 
poorly. We hope that by extrapolating from our data, you 
will be able to apply our results to your own practice. 
Dr. Frank Lo Gerfo (Boston, Mass.). I would like to 
propose a concept o you, particularly with regard to ),our 
patients operated on within 30 days in whom you have only 
a 27% graft patency rate. That concept is the mortality rate 
per graft saved. Let us say your operative mortality rate is 
2% and you wind up with a 25% long-term graft patency 
rate, the mortality rate to save 100 grafts is 8%; you have 
to multiply by 4. Beyond that is the mortality rate per limb 
saved; 75% of your grafts failed but you had only a 10% 
amputation rate. Therefore the limb was vitally dependent 
on only one in seven of those grafts, so you would have to 
then multiply the 8% by 7 so your mortality rate per limb 
saved, in that group, is about 50%. 
Dr. Belkin. I will accept that at face value. That 
subgroup is a bad group of patients; I will be very cautious 
in the future about operating on those patients because they 
do not do well. You have just enlightened me as to how 
badly they do. 
CORRECTION 
In the discussion of the original article, "Computed tomography scanning findings 
associated with rapid expansion of abdominal aortic aneurysms," by Yehuda G. Wolf, 
MD, Winston S. Thomas, MD, Frank J. Brennan, MD, Walter G. Goff, MD, Michael J. 
Sise, MD, and Eugene F. Bernstein, MD, PhD, (1994;20: 529-38), on page 538, William 
R. Fry, MD, of Oakland, Calif., was incorrectly identified as Peter D. Fry, MD, of 
Vancouver, British Columbia, Canada. 
